This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. DNA testing has led to the arrest of a ...
Potential best-in-class ATR inhibitor tuvusertib being explored in Phase II combination clinical studies; recently licensed PARP1 inhibitor M9466 to be evaluated in Phase Ib combination dose-finding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results